CHINA PHARMA HOLDINGS, INC. (CPHI) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, CHINA PHARMA HOLDINGS, INC.'s filing signal continuing negative.

China Pharma Holdings, Inc., through its wholly-owned subsidiary Hainan Helpson Medical and Biotechnology Co., Ltd., develops, manufactures, and markets pharmaceutical products in China for a range of high-incidence and high-mortality diseases. The company's product portfolio includes dry powder injectables, liquid injectables, tablets, and capsules, all approved by China's National Medical Products Administration. Helpson operates two production facilities in Haikou, Hainan Province, adhering to Good Manufacturing Practices (GMP) standards. The company focuses on generic drugs, considering market size, competition, and profit margins in its selection process, and also manufactures comprehensive healthcare and protective products. China Pharma aims to expand its distribution network and explore digital healthcare solutions and CDMO services.

Revenue is primarily driven by the sale of pharmaceutical products, including those for anti-viral/infection & respiratory, CNS cerebral & cardio vascular, digestive diseases, and other categories. The company also generates revenue from contract manufacturing organization (CMO) services.